Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan Brazeau

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Nursing Management (Harrow, London, England : 1994)|May 28, 2015
Genetically modifiedDennis J Cheek, Dan Brazeau
Pharmacogenomics|October 11, 2007
Advances in pharmacogenomics of antiretrovirals: an updateQing Ma, Dan Brazeau, Alan Forrest, et al.
Therapeutic Drug Monitoring|September 28, 2007
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoringJudianne Slish, Qing Ma, Barry S Zingman, et al.
The American Journal on Addictions|December 7, 2007
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavirNiamh Higgins, Barry S Zingman, Judianne Slish, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Nursing Management (Harrow, London, England : 1994)|May 28, 2015
Genetically modifiedDennis J Cheek, Dan Brazeau
Pharmacogenomics|October 11, 2007
Advances in pharmacogenomics of antiretrovirals: an updateQing Ma, Dan Brazeau, Alan Forrest, et al.
Therapeutic Drug Monitoring|September 28, 2007
Assessing the impact of substance use and hepatitis coinfection on atazanavir and lopinavir trough concentrations in HIV-infected patients during therapeutic drug monitoringJudianne Slish, Qing Ma, Barry S Zingman, et al.
The American Journal on Addictions|December 7, 2007
Factors associated with altered pharmacokinetics in substance users and non-substance users receiving lopinavir and atazanavirNiamh Higgins, Barry S Zingman, Judianne Slish, et al.
Pageof 1